As part of our monthly news service we would like to make you aware of the CML publications of the month. From the many papers published every month Professor Jerry Hughes has selected topical, interesting papers for your perusal that also include interesting articles from the emerging economic regions and publications on COVID-19 and CML.

Read Professor Hughes' CML publications of the month: September 2020

Clinical publications

• Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia
  Shanmunagathan N et al. Blood, September 2020 (epub ahead of print)
• Incidence of deep molecular responses and treatment-free remission in de novo CP-CMO patients
  Etienne G et al. Cancers(Basel), September 2020 - open access publication
• Erythropoietin treatment in chronic myeloid leukemia patients treated with frontline imatinib who developed anaemia
  Cesini L et al. Eur J Hematol, September 2020
• Treatment-free remission in chronic myeloid leukemia harbouring atypical BCR-ABL1 transcripts
  Dragani M et al. Mediterr J Hematol Infect Dis, September 2020 – open access publication

Scientific publications

• Efficacy of tyrosine kinase inhibitors on a mouse chronic myeloid leukemia model and chronic myeloid leukemia stem cells
  Tanaka Y et al. Exp Hematol, September 2020
• Checkpoint kinase-1 inhibitors and etoposide exhibit a strong synergistic anticancer effect on chronic myeloid leukemia cell line K562 by impairing homologenous recombination DNA damage repair
  Fan Z et al. Oncol Rep, September 2020 (epub ahead of print) - open access publication
• A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor chronic myeloid leukemia cells
  He B et al. Biomed Pharmacother, September 2020 – open access publication

ERSAP publications

• ABL kinase domain mutations in Iranian chronic myeloid leukemia patients with resistance to tyrosine kinase inhibitors
  Shojaei M et al. Lab Med, August 2020 (epub ahead of print)

COVID-19 publications

COVID-19 and CML:

• Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors
  Basci S et al. J Oncol Pharm Pract, August 2020 - open access publication

COVID-19 and haematological malignancies/cancer:

• Risk factors and outcome of COVID-19 in patients with haematological malignancies
  Piñana JL et al. Exp Hematol Oncol, August 2020 – open access publication
• COVID-19 in children with blood and cancer disorders: What do we know so far?
  Yadar SP. J Pediatr Hematol Oncol, August 2020
• Clinical characteristics and risk factors for mortality in hematologic patients affected by COVID-19
  Cattaneo C et al. Cancer, September 2020 (epub ahead of print) – open access publication
• Clinical characteristics and outcome of SARS-CoV-2-infected patients with haematological diseases: a retrospective case study in four hospitals in Italy, Spain and The Netherland
  Van Doesum J et al. Leukemia, September 2020 – open access publication

COVID-19:

• A living WHO guideline on drugs for COVID-19
  Lamontagne F et al. BMJ, September 2020
• Vaccines for COVID-19
  Tregoning JS. Clin Exp Immunol, September 2020 – open access publication